Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
about
Chemoresistance and targeted therapies in ovarian and endometrial cancersAnticancer and antimicrobial activities of some antioxidant-rich cameroonian medicinal plantsRosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathwayProfilin-1 overexpression inhibits proliferation of MDA-MB-231 breast cancer cells partly through p27kip1 upregulation.Profilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells.Cellular responses to Cisplatin-induced DNA damage.Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers.Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicinCalpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.Lifelong accumulation of bone in mice lacking Pten in osteoblastsEF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expressionDimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cellsExpression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance.Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrumCOL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilizationPI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogsPTEN in brain tumors.Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancerReduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentPotential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.PTEN and PI3K/AKT in non-small-cell lung cancer.miR-124 Acts as a Tumor Suppressor in Glioblastoma via the Inhibition of Signal Transducer and Activator of Transcription 3.Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancer.Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.MiR-200a is involved in proliferation and apoptosis in the human endometrial adenocarcinoma cell line HEC-1B by targeting the tumor suppressor PTEN.Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells.Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.Altering PI3K-Akt signalling in zebrafish embryos affects PTEN phosphorylation and gastrulation.Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer.Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma.MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
P2860
Q28073246-BC21CF35-E117-40CE-B5EF-2EE67EDD1E2BQ28486125-E23D1225-99C8-4DD7-A01C-B416076D34B9Q33554975-684409A6-A000-48DF-A6D7-5EAFBD1EA8E9Q33861827-85E2F109-B4BD-42E1-BF9D-349CE3E2C11FQ33867802-8AE293D8-20BB-4935-9E03-1083D023BD5DQ34089685-1E63A167-4BE7-47FE-82D6-42B706CC0A2BQ35167494-7CECB020-ECD7-44D8-B5D4-E547340C3F5AQ35674891-0FEFE658-9583-4D59-8CD4-FBCB4F0B5321Q35763273-E3492563-58E3-431C-8F90-9485A07E77B2Q35844528-C8F3B366-F9A4-43FC-AD23-671476A41C57Q36175652-66FB2238-1836-4952-A613-B46507D00E98Q36224281-5DF9AA51-1246-4CFF-B04C-06CA1BA69AF7Q36261565-125C57CD-522F-4989-82BC-ABAA171BE8CCQ36403630-E1576358-C654-4C46-BB8B-41978809BF4AQ36414284-E10999CC-78F8-4CB2-AEE0-5685EDCCDC9BQ36453531-9CEB8AEE-745B-4522-8D73-89C6A7C9FF8FQ36880907-1FFCF4A4-ADD0-4CB6-ACEF-412FB9F1FA24Q37139779-0095E3D1-1EDC-4A4E-889E-A021729E1798Q37257188-1340DB28-39A5-4715-8586-A26FD639E50EQ37262314-4C0E691E-CD3D-4A99-8905-F02D201FACD4Q37344348-D4571E70-208C-4914-94B1-31630D8884A9Q37420213-D19087B3-2936-4B29-AC81-454BD6FD22E7Q37708115-27EA8C61-3CB0-4752-AE24-52974400A21FQ38629644-77622AD5-DDB3-4BF6-BD26-22518C6090E9Q38784967-666933B7-7E56-4C07-B81C-C0C84AA6F1FDQ38792740-706D26EC-18A9-483D-95A6-712B2BBF4EFAQ38963051-C9C41C35-A9D9-4381-BD04-634CC9CD1C6FQ39035242-43641E64-B49E-4CA6-BA94-058CA241F34BQ39173239-D9075944-B90B-4EA7-A655-F118770DE0E5Q39588369-5E023D3F-DD46-4115-B5E4-33BE67607B46Q40024224-115C9885-9F3A-4C96-BE23-DB9CFB9F5A7DQ45974630-70A17E39-08BE-46B7-8FEF-10DC1EBF348BQ46108570-EBAC09AA-6677-49EE-83B7-679AC0ECEAAFQ48233383-FE47E1CA-9232-411F-99FD-7CD9B4BAF4BEQ50926633-E1F87A22-4FE0-442E-9F85-C51EA87772DA
P2860
Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@ast
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@en
type
label
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@ast
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@en
prefLabel
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@ast
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@en
P2093
P1433
P1476
Over-expression of PTEN sensit ...... sis in a p53-dependent manner.
@en
P2093
Michael Fraser
Xiaojuan Yan
P304
P356
10.1016/J.YGYNO.2005.12.033
P407
P577
2006-03-20T00:00:00Z